Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.

Ahmad A TarhiniImran RafiqueTheofanis FlorosPhu TranWilliam E GoodingLiza C VillaruzTimothy F BurnsDavid M FriedlandDaniel P PetroMariya FarooquiJose Gomez-GarciaAutumn Gaither-DavisSanja DacicAthanassios ArgirisMark A SocinskiLaura P StabileJill M Siegfried

Published in: Cancer (2017)

Combined rilotumumab and erlotinib had an acceptable safety profile, and the DCR met the prespecified criteria for success. In the EGFR WT group, the DCR exceeded published reports for erlotinib alone. High circulating levels of neuregulin 1 may indicate sensitivity to this combination. Cancer 2017;123:2936-44. © 2017 American Cancer Society.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
growth factor
tyrosine kinase
papillary thyroid
squamous cell
small cell lung cancer
emergency department
liver injury
squamous cell carcinoma
open label
clinical trial
adverse drug
double blind
drug induced